ACB · Aurora Cannabis Inc. · Stock research

Current Thesis

Aurora is a debt-free Canadian licensed producer re-rating on an international-medical growth engine (Germany, Poland, Australia), but the day-to-day tape treats it as high-beta sentiment exposure to a US cannabis-reschedule trade whose economics never reach it. The June 29–July 15 2026 DEA Schedule-III hearing has closed with no ALJ recommendation timeline, removing the last live near-term sentiment driver. The next hard event is the August 5 2026 Q1 FY2027 print — a transitional-year binary the company has already guided toward a revenue step-down. The stock is pinned near a $2.63 52-week low with no higher-low base. This is a structural laggard into a spent catalyst; stand aside until it bases.

Bullish and bearish views on Aurora Cannabis Inc.

The model's bull view on Aurora Cannabis Inc. (ACB), in brief: International medical is compounding and high-margin. The bear view: The live catalyst does not pay this ticker. Both cases follow in full.

Bull Case

• International medical is compounding and high-margin. FY2026 (reported June 11 2026): record global medical net revenue $289M (+18% YoY), adjusted EBITDA +32% to $54M, international medical revenue $177M — 55% of total revenue now sits outside Canada.
• Balance sheet is clean. Aurora exited FY2026 debt-free with $165M cash (June 11 2026 report), so the near-term solvency and forced-dilution overhang dogging several MSO peers is off the table.
• German franchise is winning share. Two proprietary cultivars ranked #1 and #3 by sales in Germany in the Q4/FY26 quarter (June 11 2026 call); the Leuna, Germany expansion completes in H1 FY2027 and is guided to double that site's annual flower output.
• Top-line beat on the last print. Q4/FY26 revenue $61.842M vs $55.290M consensus at a 64% adjusted gross margin (June 11 2026).
• Sell-side still nominally constructive. Consensus "Buy," average price target ~$6.16 (stale) — a wide gap the tape would reprice if the international engine outruns the Canadian drag faster than guided.

Bear Case

• The live catalyst does not pay this ticker. The April 28 2026 final order downscheduling state-medical and FDA-approved marijuana products to Schedule III — and the pending broad reschedule — are US-operator economics (GTBIF, CURLF, TCNNF, the MSOS ETF). A Canadian LP with no US THC operations only catches sentiment beta.
• The catalyst is now open-ended. The DEA hearing closed ~July 15 2026, post-hearing briefs are due August 17, and the ALJ recommendation plus administrator decision carry no announced timeline — the near-term driver is gone, replaced by a multi-quarter rulemaking process.
• FY2027 is a guided step-down. Management framed FY2027 as a transitional year: total net revenue declining toward FY2025 levels, adjusted EBITDA lower YoY, and adjusted gross margin easing to the mid-to-high 50s from 64%, driven by a ~30% cut to Canadian medical reimbursement effective April 1 2026.
• The August 5 print skews negative. Street models roughly $54.9M revenue for Q1 FY2027, a sequential decline from the $61.8M Q4 run-rate — exactly the softening the transitional-year guide telegraphs.
• Broken structure, dilutive float. A fresh $2.63 52-week low, ~59% below the $6.67 high, with the prior ~$3.07 shelf lost; a sub-$3 heavy-retail float with reverse-split and dilution history caps any sentiment pop.

Setup & Price Structure

• Price is pinned near the $2.63 52-week low inside a $2.63–$6.67 range — roughly 59% off the high with no reclaim of prior support.
• The ~$3.07 shelf cited in mid-June has been lost; price trades below its declining 50- and 200-DMA — declining-MA structure, not a base forming.
• Market cap ~$165–169M against $165M of cash means the market is valuing the operating business at close to zero, which in a chronically dilutive float reads as a value trap more than a floor.
• Any re-engagement needs an event-driven reclaim of the 50-DMA on expanding volume; absent that, expect low-dollar drift with retail-squeeze optionality only on a sector-wide sentiment spike.
• Weakness here is not an averaging opportunity — a broken sub-low print offers no structural support to lean on.

Catalyst Calendar (next 30 days)

• 2026-08-17 (confirmed): Post-hearing briefs due in the DEA Schedule-III proceeding. A procedural milestone that carries no decision; the ALJ recommendation remains undated.
• No FDA/PDUFA date or index event in the window. The next Canadian-LP-specific fundamental read is the August 5 print.

Elapsed catalysts

• 2026-08-05 (confirmed): Q1 FY2027 results, before US market open, 8:00am ET webcast. Street ~$54.9M revenue; first print under the transitional-year guide and the binary event of the window. (passed 4d ago)
• 2026-08-07 (confirmed): Virtual AGM; management information circular filed July 8 2026. Routine — watch specifically for any capital-authorization or share-issuance votes given the dilution history. (passed 2d ago)

What Would Change Our Mind

• A weekly close reclaiming the 50-DMA on expanding volume that establishes a higher low above ~$2.63 — the first genuine evidence of a base rather than continued markdown.
• An August 5 2026 print where international medical (Germany/Poland/Australia) revenue growth visibly offsets the Canadian reimbursement cut, holding consolidated revenue flat-to-up sequentially despite the guide.
• A regulatory development that actually reaches a Canadian LP — EU/German recreational-access progress or a German medical-flower volume step-up — rather than a US-recreational headline that leaves ACB's economics untouched.
• A clustered options build ahead of August 5 (call/put >2, rising IV) signalling positioning, versus the current dead tape.

Correlation Notes

• Trades as high-beta sector sentiment against the US MSO complex (MSOS ETF, GTBIF, CURLF, TCNNF), but with a structural laggard discount because the reschedule economics accrue to US operators, not a Canadian LP. Relative weakness was flagged June 4 2026 when MSOS broke out +7.6% to $5.10 while ACB stayed pinned at its low.
• Correlated to DEA-proceeding headline risk and to broad small-cap/retail risk appetite; a low-dollar, heavy-retail float amplifies moves in both directions.
• The fundamental story ties to German/EU medical-cannabis policy and EUR/CAD via $177M FY2026 international-medical revenue — a slower-moving driver than the US-sentiment beta that sets the daily tape.
• Idiosyncratic risk dominates index correlation: Canadian medical reimbursement policy (the ~30% cut effective April 1 2026) and Aurora-specific dilution history are the swing variables.